Adult non-*β* cells do not form new *β* cells during normal postnatal development or pregnancy, nor following partial pancreatectomy or partial *β* cell ablation.^[@bib1],\ [@bib2],\ [@bib3]^ Pre-existing *β* cells are thus a major source of new *β* cells under normal physiological conditions and following relatively mild injury in postnatal pancreas.^[@bib1],\ [@bib2],\ [@bib3]^ The replication potential of these cells is homogeneous^[@bib4]^ and limited by an extended delay or 'refractory period\'.^[@bib3],\ [@bib5]^

We showed that severe injury caused by partial duct ligation (PDL) in adult mouse pancreas activates a population of embryonic-type endocrine progenitor cells.^[@bib6]^ Expression of the earliest crucial transcription factor for embryogenesis of the endocrine pancreas, Neurogenin 3 (Ngn3),^[@bib7],\ [@bib8],\ [@bib9]^ was strongly activated in PDL pancreas specifically in cells near the lining of ducts.^[@bib6]^ These Ngn3^+^ cells did not derive from hormone^+^ cells and did not proliferate but, when isolated and grafted in explanted embryonic pancreas, differentiated towards functional *β* cells with elevated cell cycle activity.^[@bib6]^ Although insulin content and absolute *β* cell mass increased in the ligated part of PDL pancreas^[@bib6],\ [@bib10]^ it remains unclear whether adult Ngn3^+^ non-*β* cells contribute to *β* cell formation *in vivo*. For instance, exocrine-to-*β* cell transition in PDL pancreas has been confirmed by some^[@bib11]^ but contradicted by other reports.^[@bib12],\ [@bib13],\ [@bib14],\ [@bib15]^

The present study on *β* cell dynamics in PDL pancreas by tracing of Ngn3^+^ cells, pre-existing *β* cells, and on *β* cell proliferation shows that *β* cell neogenesis does occur in the PDL pancreas and that proliferation of both pre-existing and newly formed *β* cells increases the *β* cell volume *in vivo*.

Results
=======

Partial duct ligation generated *β* cell volume, new islets and *β* cells prone to redivide
-------------------------------------------------------------------------------------------

PDL surgery caused doubling of *β* cell mass in murine pancreas in some^[@bib6],\ [@bib10]^ but not in other studies.^[@bib12],\ [@bib15]^ Differences in tissue density between normal and duct ligated pancreas have been suggested to introduce a bias in *β* cell mass measurements,^[@bib12]^ therefore we determined *β* cell volume in the duct-ligated part of pancreas (from hereon called PDL tail) as compared with Sham-operated control pancreas (Sham tail) of Balb-c mice. Throughout this study surgery was performed on male mice of 8 weeks. *β* cell volume and islet size distribution were quantified by immunofluorescence in a semi-automated manner on 4 *μ*m thick sections, 36 *μ*m apart and spanning the whole tissue, corresponding to the analysis of 10% of the total volume of day 14 PDL- and Sham tail. The total *β* cell volume in PDL tail increased twofold as compared to Sham tail ([Figure 1a](#fig1){ref-type="fig"}). The total number of islets was increased more than twofold, specifically among the small *β* cell clusters (12--50 *μ*m diameter; ∼1--10 insulin^+^ cells on cross-section) ([Figure 1b](#fig1){ref-type="fig"}). Analysis of independent samples by automated whole-tissue optical projection tomography (OPT)^[@bib16],\ [@bib17],\ [@bib18]^ also indicated PDL-induced increase of total *β* cell volume and islet number ([Figure 1c](#fig1){ref-type="fig"}).

To study the mechanism behind this *β* cell expansion we first examined *β* cell proliferation. From hereon, quantifications were done by inspection of individual cells, in a non-automated manner. In PDL tail the percentage of insulin^+^ cells containing the proliferation marker Ki67 was increased above the normal physiological level in Sham tail or in the unligated part of PDL pancreas (termed PDL head) ([Figure 1d](#fig1){ref-type="fig"}). The percentage of *β* cells copositive for the *β* cell-specific transcription factor Nkx6.1 and for Ki67 was likewise increased ([Figure 1e](#fig1){ref-type="fig"}) indicating elevated expression of Ki67 in *β* cell nuclei. In mice that received the thymidine analog 5-iodo-2′-deoxyuridine (IdU) by intraperitoneal (i.p.) injection 8 and 4 h before sacrifice, *β* cell labeling was significantly higher in PDL tail than in Sham tail at days 7 and 14 following surgery ([Figure 1f](#fig1){ref-type="fig"}).

In (re)generation models studied so far very few *β* cells go through multiple cell cycles.^[@bib3]^ Labeling mice first with the thymidine analog 5-chloro-2′-deoxyuridine (CldU) and then with IdU allows tracing cells that have undergone one or more rounds of division *in vivo*.^[@bib3]^ To minimize the risk of misinterpretation of data we used the published antibodies for specific detection of either CldU or IdU,^[@bib3]^ verified whether these antisera reacted specifically with either analog in PDL pancreas and found no cross-reactivity ([Supplementary Figures S1A and B](#sup1){ref-type="supplementary-material"}). Second, CldU- and IdU-labeled cells were detected using fluorescent probes Cy5 and Cy2, respectively, which have minimal overlap in excitation/emission spectra ([Supplementary Figures S1C and D](#sup1){ref-type="supplementary-material"}).

As control experiment, double labeling of *β* cells was evaluated in neonatal Balb-c mice that received i.p. CldU on day 5 (P5) and i.p. IdU on P6. This resulted in high numbers of CldU-single positive and IdU-single positive *β* cells, but only very few doubly labeled *β* cells ([Figure 2a](#fig2){ref-type="fig"} and [Supplementary Figure S2A](#sup1){ref-type="supplementary-material"}). These data closely match the (re)-replication rates for neonatal *β* cells previously published by others^[@bib3]^ and support their general conclusion that *β* cells are virtually always labeled with CldU or IdU, but rarely both.^[@bib3]^ PDL surgery was immediately followed by administration of CldU and IdU via the drinking water ([Figures 2b--d](#fig2){ref-type="fig"}). At the end of the labeling period a considerable fraction of the *β* cells had re-replicated as indicated by CldU^+^IdU^+^ double labeling ([Figures 2b--d](#fig2){ref-type="fig"} and Supplementary Figures S2B--D). Following 7 days CldU and 7 days IdU labeling, 4.3±0.5% of *β* cells (5500 insulin^+^ cells counted in duct-ligated pancreas of five mice) were doubly labeled ([Figure 2c](#fig2){ref-type="fig"}) compared with the ≤1.5% reported for neonatal ([Figures 2a](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}), pregnant or pancreatectomized mice.^[@bib3]^ Quantification of CldU^+^IdU^+^ *β* cells by confocal microscopy on another set of PDL samples with 7 days CldU and 7 days IdU labeling ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}) corroborated the data obtained by fluorescence microscopy ([Figure 2c](#fig2){ref-type="fig"}). The likelihood of re-replication for *β* cells in PDL tail was \>100% for each of the labeling protocols ([Figure 2e](#fig2){ref-type="fig"}, data points of [Figures 2b--d](#fig2){ref-type="fig"}) in contrast to *β* cell proliferation in neonatal mice ([Figure 2e](#fig2){ref-type="fig"}, data point of [Figure 2a](#fig2){ref-type="fig"}) and other models ([Figure 2e](#fig2){ref-type="fig"}). This indicated that part of the *β* cells in PDL tail redivided more often than theoretically expected from stochastic kinetics, representing a subpopulation of *β* cells in PDL tail that preferentially cycle.

Continuous thymidine analog labeling during 7, 14 or 35 days showed long-term subsistence of a higher proliferation potential by *β* cells in small clusters of 1--20 insulin^+^ cells in PDL tail ([Figures 3a--c](#fig3){ref-type="fig"}, respectively). At 35 days post-PDL the majority of clusters with ≤20 insulin^+^ cells consisted entirely of insulin^+^ cells that had divided ([Figure 3d](#fig3){ref-type="fig"}), indicating that the majority of small islets are generated through replication. In addition, consecutive labeling with CldU and IdU showed that the rate of redivision by *β* cells in PDL tail was highest in small clusters ([Figure 3e](#fig3){ref-type="fig"}). IdU pulse labeling indicated different proliferation kinetics in small and large (21--200 insulin^+^ cells) clusters of PDL tail, but no changes in the corresponding *β* cell populations of Sham tail ([Figure 3f](#fig3){ref-type="fig"}). These results assign small islets as the preferential site for *β* cell (re)division. On the basis of the IdU pulse label and volumetric assay of *β* cells in PDL and Sham tail pancreas, the *β* cell growth was mathematically modeled. The calculations suggested that proliferation of pre-existing *β* cells can account for 86% of the *β* cell expansion observed in PDL tail ([Supplementary Figure S4A](#sup1){ref-type="supplementary-material"}) and that small clusters present at day 7 of PDL can expand their *β* cell numbers nearly threefold in the second week of PDL to generate larger clusters ([Supplementary Figure S4B](#sup1){ref-type="supplementary-material"}).

*β* cells derived from Ngn3^+^ cells locate preferentially in small islets and proliferate
------------------------------------------------------------------------------------------

Ngn3^CreERT^;R26^YFP^ mice^[@bib19],\ [@bib20]^ were generated to evaluate possible contribution of progenitors to *β* cell growth by permanent tracing of cells with activated Ngn3 and descendants thereof. These cells constitutively express the reporter protein YFP once the stop sequence that prevents reporter gene expression is removed ([Figure 4a](#fig4){ref-type="fig"}) upon treatment of mice with tamoxifen (TAM). Male Ngn3^CreERT^;R26^YFP^ mice of 8 weeks underwent PDL surgery, were subcutaneously injected with TAM and were sacrificed at day 14 post-PDL ([Figure 4a](#fig4){ref-type="fig"}). As Ngn3 progenitors could be activated at any time-point following PDL and the Ngn3 promoter activity in these cells is transient,^[@bib6],\ [@bib9]^ repeated injections of tamoxifen were applied (starting at the day of surgery: s.c. injection of 4 mg, repeated once-every-other-day, five injections in total) for maximizing the number of labeled progenitors ([Figure 4a](#fig4){ref-type="fig"}). YFP was expressed in enteroendocrine cells of duodenum ([Supplementary Figure S5A](#sup1){ref-type="supplementary-material"}), in cytokeratin19^+^ (CK19^+^) and insulin^+^ (INS^+^) cells located along the duct lining ([Supplementary Figures S5B and C](#sup1){ref-type="supplementary-material"}), and in small clusters of CK19^+^ INS^+^ cells associated with ducts ([Figure 4b](#fig4){ref-type="fig"}). The fraction of YFP^+^ *β* cells in islets ([Figure 4c](#fig4){ref-type="fig"}, [Supplementary Figure S5D](#sup1){ref-type="supplementary-material"}) increased with Ngn3 transcript level in PDL tail but not in PDL head ([Figure 4d](#fig4){ref-type="fig"}). These results suggest that the contribution of Ngn3^+^ cells to *β*-cell neogenesis correlates to the level of Ngn3 gene expression following injury. In PDL tails with a Ngn3 transcript level above 60% of duodenum, 39.4±3.2% of *β* cells were YFP^+^ in small *versus* 15.4±1.1% in large clusters, at day 35 post-PDL ([Figure 4e](#fig4){ref-type="fig"}). In PDL head, no such difference was found (0.6±0.6% YFP labeling of *β* cells in small clusters *versus* 1.49±0.16% in large clusters, *P*\>0.05, *n*=9). Labeling mice with the thymidine analog IdU via the drinking water indicated that a large fraction of YFP^+^ *β* cells in PDL tail pancreas was involved in proliferation and that YFP^+^ insulin^+^ cells proliferated more in small than in large *β* cell clusters ([Figure 4f](#fig4){ref-type="fig"}).

New *β* cells dilute pre-existing *β* cells in PDL islets
---------------------------------------------------------

To investigate whether in PDL pancreas *β* cells can also derive from non-*β* cells, the ratio between pre-existing and newly formed *β* cells was investigated in RIP^CreERT^;R26^LacZ^ mice^[@bib1]^ ([Figure 5a](#fig5){ref-type="fig"}). Following TAM-treatment, washout and PDL surgery, mice were sacrificed after a 14 or 35 days chase period ([Figure 5a](#fig5){ref-type="fig"}). PDL tails with high Ngn3 mRNA (\>60% of duodenum transcript level) were analyzed for the presence of bGal^+^ *β* cells and compared with PDL head of the same pancreas. In PDL head 82±5% of *β* cells (6720 INS^+^ cells counted in three mice) expressed bGal, representing the labeling efficiency at day 14 post-PDL ([Figure 5b](#fig5){ref-type="fig"}). In PDL tail of the same mice, 74±6% of all *β* cells (8216 insulin^+^ cells counted) was bGal^+^ ([Figure 5b](#fig5){ref-type="fig"}). During 14 days following surgery pre-existing *β* cells had been diluted by unlabeled newly formed *β* cells in small islets of PDL tail only ([Figure 5b](#fig5){ref-type="fig"}). An extended post-PDL chase period of 35 days resulted in a statistically significant decrease (70±4% *versus* 82.5±0.3%) in preponderance of bGal^+^ *β* cells in PDL tail (14510 INS^+^ cells counted in three mice) as compared with PDL head (13544 INS^+^ cells counted) ([Figure 5c](#fig5){ref-type="fig"}). The dilution of labeled cells indicated that up to 14.6% of all *β* cells and 42% of *β* cells in small islets in PDL tail derived from non-*β* cells ([Supplementary Figure S4C](#sup1){ref-type="supplementary-material"}). The preponderance of bGal^+^ *β* cells at day 35 was significantly decreased in islets of various sizes in PDL tail ([Figure 5c](#fig5){ref-type="fig"}). Remarkable were islets that consisted nearly entirely of bGal^−^ insulin^+^ cells ([Figure 5d](#fig5){ref-type="fig"}, [Supplementary Figure S6](#sup1){ref-type="supplementary-material"}) whereas bGal^+^ insulin^+^ cells predominated in islets of PDL head of the same mice ([Figure 5e](#fig5){ref-type="fig"}, [Supplementary Figure S6](#sup1){ref-type="supplementary-material"}). With an average of 70% bGal^+^ *β* cells in PDL tail ([Figure 5c](#fig5){ref-type="fig"}), binomial probability calculation results in a chance of 5.4 × 10^−7^ for any islet with 20 *β* cells of having only three or less bGal^+^ *β* cells. In reality, 12 out of 186 islets with 20--200 *β* cells (=6.4 × 10^−2^) were found with three or less bGal^+^ *β* cells in PDL tail. In PDL head of these mice, no such islets were observed (276 large islets inspected). This finding excludes that these islets with strongly diluted label arose by chance. Similar results were obtained in independent experiments using RIP^CreERT^;R26^YFP^ mice^[@bib20],\ [@bib21]^ ([Supplementary Figure S7](#sup1){ref-type="supplementary-material"}). The active dilution of pre-existing labeled *β* cells in PDL tail supports a process of *β* cell neogenesis from non-*β* cells.

Ngn3^+^ non-*β* cells are required for *β* cell formation in PDL pancreas
-------------------------------------------------------------------------

Above results suggested that expansion of the *β* cell mass in PDL pancreas correlates with activation of Ngn3 gene expression and occurs by proliferation of both pre-existing and newly formed *β* cells. To address the role of Ngn3^+^ cells in *β* cell expansion, the effect of their selective ablation was studied. Ngn3^CreERT^;R26^iDTR^ mice were generated to constitutively express simian diphtheria toxin receptor (DTR) following removal of a transcriptional STOP cassette^[@bib22]^ by inducible CreERT recombinase whose expression is controlled by the Ngn3 promoter.^[@bib19]^ Administration of diphtheria toxin (DT) to R26^iDTR+/+^ mice specifically and efficiently kills cells that have undergone Cre-mediated deletion of the STOP sequence.^[@bib22]^ PDL surgery and TAM administration to Ngn3^CreERT−/+^;R26^iDTR+/+^ mice or Ngn3^CreERT−/−^;R26^iDTR+/+^ control littermates was followed by i.v. injection of DT ([Figure 6a](#fig6){ref-type="fig"}). On the basis of the Ngn3 transcript level, 77% of Ngn3^+^ enteroendocrine progenitor cells in duodenum and 66% of Ngn3^+^ cells in PDL tail could be ablated ([Figure 6b](#fig6){ref-type="fig"}), resulting in 28% decrease in insulin content ([Figure 6c](#fig6){ref-type="fig"}). In contrast, DT treatment did not affect the insulin content in PDL head ([Figure 6c](#fig6){ref-type="fig"}). Ablation of Ngn3^+^ cells reduced *β* cell proliferation by 53% in PDL tail, while in PDL head no effect on *β* cell proliferation was observed ([Figure 6d](#fig6){ref-type="fig"}). These data suggests that both the insulin content and the *β* cell proliferation partially depend on Ngn3^+^ cells in PDL tail. Strikingly, in small clusters of 1--20 *β* cells, *β* cell proliferation was reduced by 66% ([Figure 6e](#fig6){ref-type="fig"}), suggesting complete dependence on Ngn3^+^ cells. DT treatment of Ngn3^CreERT−/+^;R26^iDTR+/+^, Sham operated mice showed no effect on insulin content, nor on *β* cell proliferation ([Supplementary Figure S8](#sup1){ref-type="supplementary-material"}). Together the results indicate that Ngn3^+^ cells are required for the expansion of *β* cells in PDL pancreas, while in normal pancreas Ngn3^+^ cells do not contribute to the generation of *β* cells.

To address whether the expression of Ngn3 in pre-existing *β* cells have a role in *β* cell expansion following PDL, the Ngn3 gene was conditionally inactivated in mature *β* cells of RIP^CreERT^;Ngn3^lox/lox^ mice^[@bib1],\ [@bib19]^ before PDL surgery. Five-week-old mice were TAM-injected followed by a washout period, and PDL surgery was performed at week 8 of age. At day 14 postsurgery, the *β* cell proliferation rate in PDL tail of pancreas in RIP^CreERT^;Ngn3^lox/lox^ mice was not different from that in RIP^CreERT^;Ngn3^+/+^ mice ([Figure 6f](#fig6){ref-type="fig"}). The efficiency of Ngn3 inactivation in *β* cells, was evaluated in RIP^CreERT^;R26^YFP^;Ngn3^+/lox^ mice that had received TAM as before. After islet isolation and dissociation, islet cells were sorted on basis of TSQ (TSQ^high^ marks endocrine cells^[@bib6]^) and YFP fluorescence, which showed that 79±1% (*n*=4) of TSQ^high^ islet cells were also YFP^+^, representing *β* cells with Cre activation. Moreover, amplification of DNA extracted from YFP^+^ *β* cells using Ngn3^lox^-specific primers revealed that these cells had completely lost their Ngn3^lox^ allele in contrast to the YFP^−^ islet cells ([Figure 6g](#fig6){ref-type="fig"}). Together, the data suggest that deletion of Ngn3 in pre-existing *β* cells occurred very efficiently, and that Ngn3 in non-*β* and newly formed *β* cells rather than in pre-existing *β* cells was required for *β* cell proliferation and expansion observed in PDL pancreas.

Discussion
==========

Our previous findings indicated that upon PDL surgery *β* cells expand and Ngn3^+^ endocrine progenitors are activated.^[@bib6]^ In the present study, we examined relative contributions of neogenesis and proliferation to the expansion of *β* cells. For evaluation of the impact by proliferation of pre-existing *β* cells, three parameters were determined: *β* cell expansion, proliferation rates, and the mode of *β* cell replication. Total *β* cell volume doubled and *β* cells proliferated more in PDL tail pancreas without restriction to re-engage in cycling. Modeling *β* cell proliferation according to these parameters suggests that 86% of *β* cells in PDL tail pancreas at 14 days postsurgery derive from pre-existing ones. Dilution of permanently labeled pre-existing *β* cells^[@bib1]^ indicated that 14.6% of the total *β* cell population derived from non-*β* cells. PDL increased the total number of islets and in particular the number of small islets where 42% of *β* cells derived from a non-*β* cell origin and the *β* cell cycling activity was high. The small islets can give rise to larger ones within 14 days. The majority of small clusters were composed entirely of dividing *β* cells and there was evidence for large clusters of \>20 *β* cells on cross-section that consisted nearly entirely of new *β* cells, while no such islets were found in the unligated part of PDL pancreas. Taken together, our findings show that both neoformation and proliferation of *β* cells contribute to the *β* cell expansion in adult PDL pancreas. We confirm previous findings^[@bib4]^ that in adult normal pancreas *β* cells in different islets appear to have an equal potential for growth but show that this is not the case in PDL pancreas where small islets are foci for *β* cell (re)-replication and neogenesis. The possibility to trigger the formation of islets with replication-prone *β* cells opens a new perspective for regenerative strategies.

Permanent genetic tracing of cells that activated Ngn3 gene expression detected up to 40% of label^+^ *β* cells in small clusters in PDL. Similar fractions of newly formed label^−^ *β* cells were observed by *β* cell tracing in PDL pancreas suggesting that the Ngn3^+^ cells were newly formed *β* cells. Although Ngn3 expression has also been reported in mature *β* cells of normal pancreas,^[@bib19]^ we found only few label^+^ *β* cells in Sham tail and PDL head pancreas of Ngn3^+^ cell tracer mice. Moreover, conditional ablation of Ngn3^+^ cells had no effect on the insulin content or *β* cell proliferation in PDL head or Sham tail pancreas, suggesting either no influence of Ngn3^+^ *β* cells on these parameters or a too low expression level of Ngn3 in *β* cells to cause Cre-induced recombination. In contrast, DT-ablation of part of the Ngn3^+^ cells in PDL tail reduced both insulin content and *β* cell proliferation. This corroborates our previous finding that knockdown of Ngn3 in PDL pancreas reduces *β* cell proliferation and mass expansion.^[@bib6]^ Thus, unlike in adult normal pancreas, *β* cell expansion in PDL depends on Ngn3^+^ cells. Inactivation of the Ngn3 gene in pre-existing *β* cells does not affect *β* cell proliferation in PDL tail pancreas suggesting that Ngn3^+^ non-*β* cells or newly formed *β* cells are important for stimulating proliferation as the main mechanism of *β* cell expansion in PDL pancreas. We cannot presently exclude that *β* cells under these conditions are more stressed than in normal conditions, which may enhance *β* cell expression of Ngn3^[@bib23]^ and dedifferentiation to progenitor-like Ngn3^+^ cells.^[@bib24]^ We have not observed increased activation of caspase-3 in PDL *β* cells (^[@bib6]^ and unpublished results), and *β* cells isolated from PDL pancreas did not show decreased Foxo1, Ins1 or Ins2 mRNA expression (unpublished data), which seems to argue against dedifferentiation under stress. Nevertheless, this requires more investigation. As only a small proportion of all *β* cells derived from Ngn3^+^ cells but 53% of *β* cell proliferation was prevented by ablation of the Ngn3^+^ cells, our data suggest non cell autonomous stimulation of *β* cell proliferation by Ngn3^+^ cells in PDL. Our finding of newly-formed but also pre-existing *β* cells with high cycling activity within small clusters suggests that the microenvironment of small islets in PDL have a role in enhanced recruitment of *β* cells into cycling.

The inconsistent outcome of PDL in terms of *β*-cell neogenesis^[@bib12],\ [@bib13],\ [@bib14]^ in recent studies may be explained by differences in activation of Ngn3 gene expression. Our data suggest *β*-cell neogenesis to correlate with Ngn3 gene expression following PDL, arguing in favor of a threshold below which reprogramming will not be stimulated ---a principle that has been described before^[@bib25]^--- and providing us with a way to screen for conditions and drugs favoring this process. In view of our present data, relatively poor activation of Ngn3 gene expression in PDL pancreas as reported by some^[@bib12],\ [@bib13]^ is an unfavorable condition for *β*-cell neogenesis. On the other hand, our present data on Ngn3 tracing and dilution of pre-existing *β* cells indicate that direct derivation of *β* cells from Ngn3^+^ non-*β* cells in PDL is not as high as initially claimed in Xu *et al.*[@bib6], even in PDL pancreas with strong Ngn3 gene induction.

We do find, however, that Ngn3^+^ non-*β* cells are key to the *in vivo* expansion of *β* cells and generation of replication-prone *β* cells in injured adult pancreas. A mechanistic role for Ngn3^+^ cell activation in *β* cell formation in PDL is supported by the correlation between Ngn3-transcript levels and the preponderance of Ngn3^+^ cells on the one hand and the finding that *β* cell proliferation depends on Ngn3^+^ cells on the other. Our findings provide a platform for characterization of the signals that control neogenesis and *β* cell proliferation in the adult pancreas and may be drug targets for regenerative treatment of diabetes.

Materials and Methods
=====================

Mouse manipulation
------------------

All mice experiments were performed according to the guidelines of our institutional 'Ethical Committee for Animal Experiments\' and national guidelines and regulations. Pancreatic duct ligation or Sham operation were performed as described.^[@bib6],\ [@bib10]^

Cell tracing
------------

Mice were continuously labeled by administering CldU, IdU, in drinking water bottles at 1 mg/ml^3^. CldU (C6891) and IdU (347580) were obtained from Sigma Aldrich (Diegem, Belgium).

Tamoxifen (Sigma, T5648) was dissolved at 10 mg/ml in corn oil (Sigma, C8267). For PDL studies in adult mice, a total of 20 mg of tamoxifen (TAM) was given s.c. in five doses (each 4 mg) over a 2-week period. In Ngn3^CreERT^;R26^iDTR^ mice, diphtheria toxin was given (three tail vein injections of 125 ng each) during the last 3 days of the post-PDL period.

*β* cell volume and insulin content
-----------------------------------

The measurement of *β* cell volume (mm^3^) in PDL or Sham tail pancreas was performed as described previously.^[@bib6]^ Analysis of each organ was based on a large number of 4 *μ*m-sections equally spaced and spanning the whole tissue, together representing 10% of the total volume. Measurement of pancreas insulin content was done as described^[@bib26]^ as well as OPT 3D analysis.^[@bib16]^

Immunolocalization and histochemical procedures
-----------------------------------------------

Samples for immunohistochemistry were fixed in 4% formaldehyde overnight and embedded in paraffin. Paraffin sections (4--5 *μ*m) were incubated with antisera specific for insulin (1/3000, guinea pig, generated at the Diabetes Research Center, Brussels, Belgium), glucagon (1/3000, rabbit), Nkx6.1 (1/2000, rabbit, Beta cell biology consortium, Nashville, TN, USA), Ki67 (1/1000, rabbit, Novocastra, Leica Microsystems, Diegem, Belgium), CK19 (1/100, rat, DSHB, University of Iowa, Iowa, USA), GFP (1/100, goat, Abcam, Cambridge, UK), anti *β*-galactosidase (bGal) (1/500, rabbit, Invitrogen, Life Technologies, Ghent, Belgium), anti-BrdU antisera (IdU) (1/100, mouse, BD Biosciences, Erembodegem, Belgium) and anti-CldU antisera (1/250, rat, Gentaur molecular products, Kampenhout, Belgium). Antigen retrieval was required for recognition of thymidine analogs (microwaved in 0.01 ℳ sodium citrate, permeabilized with 1% Triton, incubated in 1.5 𝒩 HCL) and CK19 (citrate buffer). Secondary antibodies for detection of guinea pig, rabbit, goat or rat antibodies were labeled by fluorescence (Cy3, Cy2, Cy5 or AMCA) (Jackson Immuno-Research Labs, Suffolk, UK). Nuclei were labeled by Hoechst 33342 (4 mg/ml, Sigma).

Image analysis
--------------

Images were acquired with a normal (Olympus, Aartselaar, Belgium, BX61 with Hamamatsu C10600 ORKA-R^2^ camera) or confocal scanning (Leica, Aartselaar, Belgium, TCS-SP and Zeiss (Carl Zeiss, Zaventem, Belgium) LSM710 NLO) microscopy. CldU-, IdU- or CldU- and IdU-positive or Ki67/bGal/YFP-expressing cells were counted separately and localization within insulin^+^ (*β*) cells was checked individually. At least 3000 *β* cells per sample were counted unless stated otherwise. Images were analyzed using Smartcapture 3 (version 3.0.8, Cambridge, UK), NIH ImageJ (U.S. National Institutes of Health, Bethesda, MD, USA) and Photoshop CS (version 1.3.1, Adobe, San Jose, CA, USA). Confocal images were processed using Improvision Volocity LE (Perkin Elmer, Zaventem, Belgium) and Zeiss Zen software (Carl Zeiss).

RNA and DNA analysis
--------------------

Total RNA was isolated from tissue (RNeasy, QIAGEN, Venlo, Netherlands). Only RNA with RNA Integrity Number R≥7 (2100 BioAnalyzer, Agilent, Diegem, Belgium) was further analyzed. cDNA synthesis and RT-PCR were done using mouse-specific primers and probes recognizing Ngn3 and cyclophilin A (Mm02342429) with TaqMan Universal PCR master mix on an ABI Prism 7700 Sequence Detector, and data were analyzed using the Sequence Detection Systems Software, version 1.9.1 (all Applied Biosystems, Life Technologies). The following sequences were used for analysis of Ngn3: 5′-GTCGGGAGAACTAGGATGGC-3′ (forward primer), 5′GGAGCAGTCCCTAGGTATG-3′ (reverse primer) and 5′-CGGAGCCTCGGACCACGAA-3′go (probe). Quantitative PCR reactions were then performed with cDNA corresponding to 20 ng RNA as described.^[@bib6]^ Data were normalized to cyclophilin A, and expressed relative to values obtained for duodenum samples, which were the internal reference for Ngn3 expression.

Pancreatic islets were isolated and dissociated, and islet cells sorted by FACS, as previously described.^[@bib6],\ [@bib26]^ Islet cell DNA was extracted using the DNeasy blood and tissue 250 kit (Qiagen; cat.no.69506). Screening for Ngn3^lox^ and Ngn3^+^ alleles in islet cells was by classical PCR on genomic DNA using primers 722+723, as described.^[@bib27]^ These primers do not amplify the Ngn3^−^ allele that is produced by Cre-mediated deletion of Ngn3^lox^.

Statistics
----------

Data are expressed as mean±S.E.M. of at least three independent experiments. Differences between data were analyzed by unpaired two-tailed student\'s *t*-test, one-way ANOVA, or two-way ANOVA with Bonferroni *post hoc*-test, and were considered statistically significant when *P*\<0.05.
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![PDL induces islet formation and *β* cell proliferation in adult mouse pancreas. Eight-week-old male Balb-c mice, underwent PDL or Sham surgery. (**a**) PDL and Sham tail total *β* cell volume (mm^3^) and (**b**) number of *β* cell clusters in the indicated diameter (*μ*m) categories (*n*=3; \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001, ns: *P*\>0.05, PDL *versus* Sham tail). (**c**) Panels show the total tissue volume (gray) and insulin^+^ volumes (red) detected by OPT microscopy in tail regions of Sham or PDL operated pancreases. The total islet volume increased after PDL to 2.0 × 10^9^±3.5 × 10^8^ μm^3^ (compared with Sham tail 1.1 × 10^9^±2.8 × 10^8^ μm^3^; *n*=3; *P*=0.056). The total number of insulin^+^ islets significantly increased from 1000±184 in Sham to 1539±77 in PDL tails (*n*=3; *P*\<0.05). This increase could be attributed to a significant increase in small islets (\<10^6^ μm^3^) (711±107 islets in Sham *versus* 1082±25 islets in PDL; *n*=3; *P*\<0.05). (**d**,**e**) *β* cell proliferation was determined in ligated PDL tail, unligated PDL head or Sham tail pancreas, at 7 and 14 days post-PDL by immunofluorescence staining (**d**) for insulin and Ki67 (*n*=5--14) or (**e**) for insulin, Nkx6.1 and Ki67 (*n*=3) (\*\*\**P*\<0.001, ns: *P*\>0.05, *versus* Sham tail or PDL head by two-way ANOVA). (**f**) 5-iodo-2′-deoxyuridine (IdU, 1 mg/ml) was i.p. injected precisely at 8 and 4 h before sacrifice at the indicated time points following PDL. The percentage of IdU-labeled *β* cells was determined by immunostaining for insulin and IdU (*n*=3, \**P*\<0.05, \*\**P*\<0.01 *versus* Sham tail by two-way ANOVA). 1800±200 *β* cells were counted per tissue sample. See also [Supplementary Figure S4A](#sup1){ref-type="supplementary-material"}](cddis201352f1){#fig1}

![*β* cells of PDL pancreas redivide without extended delay ('refractory period'). Insulin^+^ *β* cells were scored for CldU and/or IdU labeling using analog-specific antibodies. By labeling a first cell division with CldU (blue) and a second one with IdU (green), sequential divisions result in colabeled *β* cells (blue and green). (**a**) Neonatal Balb-c mice received i.p. CldU on day 5 (P5), and i.p. IdU on postnatal day 6 (P6), and were sacrificed 24 h later. P6 mice pancreas displayed high percentages of CldU-single positive (blue nuclei) and IdU-single positive (green nuclei) *β* cells (red) but only very few double-labeled CldU^+^IdU^+^ *β* cells (blue and green nuclei). (*n*=6, 7316 insulin^+^ cells evaluated). Eight-week-old male Balb-c mice underwent PDL surgery and CldU and IdU were sequentially administered via the drinking water: (**b**) 3 days CldU+3 days IdU (*n*=6, 8172 *β* cells counted), (**c**) 7 days CldU+7 days IdU (*n*=5, 5505 *β* cells counted), (**d**) 7 days CldU+28 days IdU (*n*=3, 5816 *β* cells counted). (**e**) On the basis of the data obtained in (**a**--**d)**, the likelihood of redivision of *β* cells was calculated (see formula) and plotted *versus* duration of the cognate IdU labeling period, fitting the modeled exponential function **f(x)=(1-a**^**x-r**^**)/(1-a**^**x**^), where **x**=days of IdU labeling, **a**=probability of non-labeling per day and **r**=refractory period in days. The curve fitted the experimental PDL data (**b**--**d**), as well as data obtained by^[@bib3]^ for partial pancreatectomy (PPx), pregnant mice (Preg), neonatal mice (Neo), or non-treated mice (non-treated). For comparison, our data on neonatal mice (**a**) are also represented by a datapoint (\*) in (**e**). See also [Supplementary Figures S2 and S3](#sup1){ref-type="supplementary-material"}. Scale bars represent 50 *μ*m](cddis201352f2){#fig2}

![Small *β* cell clusters are the preferred site of *β* cell (re)division in PDL pancreas. Eight-week-old male Balb-c mice underwent PDL surgery and were continuously labeled with thymidine analogs via the drinking water. Proliferation was analyzed by immunofluorescence staining for either IdU or IdU and CldU in insulin^+^ cells. Small clusters were defined as clusters of 1--20 *β* cells on cross-section while large clusters contained 21--200 *β* cells. Data are expressed as mean±S.E.M. of the percentage of *β* cells that were positive for thymidine analog in each size category. (**a**) Seven days IdU-labeling of *β* cells in PDL tail (*n*=5, \*\**P*\<0.005), (**b**) 14 days IdU-labeling of *β* cells in PDL head and tail (*n*=4--7, \**P*\<0.02, ns: *P*\>0.05). (**c**) Thirty-five days of IdU-labeling of *β* cells in the PDL tail (*n*=3, \*\**P*\<0.01). (**d**) Data from (**c)** analyzed for subcategories of clusters, and expressed as the percentage of clusters consisting of only analog^+^ *β* cells. Clusters comprising \>60 insulin^+^ cells never consisted entirely of analog^+^ *β* cells. (*n*=3, \*\**P*\<0.01 by one-way Anova) (**e**) 7 days CldU labeling followed by 28 days IdU labeling and evaluation of the percentage of CldU^+^IdU^+^ labeled (redivided) *β* cells according to cluster size (*n*=3, \*\**P*\<0.01 by one-way Anova). (**f**) 8 h IdU pulse labeling of *β* cells in small and large clusters of PDL and Sham tail pancreas (*n*=3; \**P*\<0.05, \*\**P*\<0.01 *versus* same time point for Sham tail, by 2-way Anova). See also [Supplementary Figure S4B](#sup1){ref-type="supplementary-material"}](cddis201352f3){#fig3}

![*β* cells derived from Ngn3^+^ cells preferentially locate and proliferate in small *β* cell clusters of PDL pancreas. (**a**) Description of the transgenic mouse model and the labeling strategy for heritable tracing of Ngn3 expressing cells. Ngn3=Ngn3 gene promoter, R26=Rosa26 locus, loxP=loxP sequence, STOP=transcriptional STOP sequence, YFP=yellow fluorescent protein. Tamoxifen injection (TAM, \*4 mg/injection) of bigenic Ngn3^CreERT^;R26^YFP^ mice results in Cre-mediated removal of the lox-P flanked STOP sequence, and permanent expression of the YFP reporter gene in cells with an active Ngn3 promoter and their descendants. Eight-week-old male bigenic mice underwent PDL surgery and were TAM-injected (s.c., starting on day of surgery: 4 mg TAM, repeated once every-other-day, five injections in total). (**b**) YFP-staining in small clusters of Insulin^+^CK19^+^ cells associated with CK19^+^ duct cells of PDL tail. (**c**) YFP^+^INS^+^ *β* cells in islets of PDL tail. (**d**) Quantification of the percentage YFP^+^ *β* cells in PDL head and tail with the indicated range of Ngn3 mRNA expression level in PDL tail 14 days after ligation (*n*=3, \**P*\<0.05, \*\**P*\<0.01 by two-way ANOVA; a total of 21295 *β* cells evaluated). Ngn3 mRNA was expressed relative to cyclophilin A mRNA and normalized to Ngn3 expression in duodenum. (**e**) Quantification of the percentage of YFP^+^ *β* cells in small (1--20 insulin^+^ cells) and large (21--200 insulin^+^ cells) clusters in PDL tail day 14 and 35 (three mice per experimental condition, \*\*\**P*\<0.001 *versus* large clusters, by two-way ANOVA). (**f**) Quantification of percentage IdU-labeling (proliferation) in YFP^+^ *β* cells in small and large clusters (*n*=3, \**P*\<0.05, *versus* large clusters). (See also [Supplementary Figure S5](#sup1){ref-type="supplementary-material"}). Scale bars represent 50 *μ*m](cddis201352f4){#fig4}

![New *β* cells can derive from non-*β* cells in PDL pancreas. (**a**) Description of the transgenic mouse and the strategy for labeling and tracing pre-existing *β* cells (legend as in [Figure 4](#fig4){ref-type="fig"}). Tamoxifen s.c. injection (\*TAM, 4 mg/injection) of bigenic RIPCre^ERT^;R26^lacZ^ mice of 8 weeks results in transient nuclear translocation of CreERT, leading to removal of the loxP-flanked STOP sequence and permanent heritable expression of the lacZ reporter gene (encoding *β* galactosidase, bGal) in *β* cells. A 14 days TAM-washout (WO) period assured the absence of residual TAM at the time of surgery. PDL-surgery was followed by a label-chase period of 14 or 35 days after which islets in PDL head or PDL tail were examined by immunostaining for bGal expression in insulin^+^ cells. Non *β* cell-derived *β* cells would dilute the label and decrease the preponderance of bGal^+^ insulin^+^ cells. (**b**) bGal expression in insulin^+^ cells following 14 or (**c**) 35-days chase period. Left panels, preponderance of bGal^+^ insulin^+^ cells; right panels, preponderance of bGal^+^ insulin^+^ cells in clusters of different sizes. Data are expressed as the mean±S.E.M. obtained with three mice (\**P*\<0.05, \*\**P*\<0.01). (**d**) Immunofluorescent staining for detection of pre-existing (bGal^+^ insulin^+^) *β* cells in PDL tail and (**e**) in PDL head, after 35 days chase period. (See also [Supplementary Figures S4C,S6 and S7](#sup1){ref-type="supplementary-material"}). Scale bars represent 50 *μ*m](cddis201352f5){#fig5}

![Ngn3^+^ cells are required while Ngn3 in pre-existing *β* cells is dispensable for the *β* cell proliferation in PDL pancreas. (**a**) Description of the transgenic mouse model and strategy used for selective ablation of Ngn3^+^ cells by DT. Tamoxifen injection in bigenic Ngn3Cre^ERT−/+^;R26^iDTR+/+^ mice results in permanent heritable expression of the DTR gene in Ngn3^+^ cells and cells derived thereof. Eight-week-old bigenic mice and monogenic Ngn3Cre^ERT−/−^;R26^iDTR+/+^ littermates underwent PDL surgery, s.c. TAM administration (\*TAM, 4 mg/injection), and i.v. DT (\# daily injections, 125 ng/injection). (**b**) Ngn3 mRNA expression measured by qRT-PCR in duodenum, and PDL head and tail pancreas of mono- (*n*=3) or bigenic mice (*n*=4; \**P*\<0.05 *versus* the monogenic tissue). Data were normalized to cyclophilin A mRNA and expressed relative to the Ngn3 level in monogenic duodenum. (**c**) Total insulin content (*μ*g) of PDL head and tail pancreas of mono- or bigenic mice (*n*=3, \*\**P*\<0.01). (**d**) Percentage of Ki67^+^ *β* cells in PDL head and tail pancreas of mono- (*n*=3) or bigenic (*n*=4) mice (\*\**P*\<0.02). (**e**) Percentage of Ki67^+^ *β* cells in small (1--20) or large (21--200) cell clusters of PDL tail (*n*=3--4, \**P*\<0.05, ns: *P*\>0.05 by two-way ANOVA). Data are expressed as the mean±S.E.M. See also [Supplementary Figure S8](#sup1){ref-type="supplementary-material"}. (**f**) Following TAM injection and wash out, RIP^CreERT^;Ngn3^+/+^ and RIP^CreERT^;Ngn3^lox/lox^ mice underwent PDL surgery. Immunofluorescence staining for Ki67 and insulin in PDL tail tissues is shown. *β* cell proliferation was quantified and expressed as the mean±S.E.M. (*n*=6, ns: *P*\>0.05; a total of 30250 *β* cells were evaluated). Scale bar represents 50 *μ*m. (**g**) RIP^CreERT^;R26^YFP^;Ngn3^+/lox^ mice were treated with TAM as in (**f**). Islets were isolated and dissociated to sort the islet cells on the basis of TSQ (Dapi, not shown) and YFP fluorescence (FITC). The window (left panel) comprises all the TSQ^high^ (endocrine) cells. The gating indicates YFP^+^ *β* cells (green dots). YFP^−^ islet cells (red dots) were also collected. YFP^−^ islet cells had a wild-type (Ngn3^+^) and a floxed (Ngn3^lox^) allele, whereas YFP^+^ *β* cells had lost the Ngn3^lox^ allele. PCR results for two separate isolations are shown (right panel)](cddis201352f6){#fig6}
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